Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03936361 · ClinicalTrials.gov registry record · Phase 3
Statins In Intracerbral Hemorrhage
A Phase 3 study of Intracerebral Hemorrhage, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 1,456
- Enrollment target
- 1
- Study location
NCT03936361 is a Phase 3 study of Intracerebral Hemorrhage that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 1,456 participants, above the 1,126-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (29% higher). The trial reports 1 study location across 1 state.
The verdict
NCT03936361, a Phase 3 study of Intracerebral Hemorrhage, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,456 participants
- Enrollment target
- 1
- Study location
Study Summary
The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. An MRI ancillary study (SATURN MRI), in a subset of SATURN participants , will evaluate the effects of continuation vs. discontinuation of statin drugs on hemorrhagic and ischemic MRI markers of cerebral small vessel disease, and whether the presence/burden of hemorrhagic markers (i.e. cerebral microbleeds and/or cortical superficial siderosis) on baseline MRI influences the risk of ICH recurrence on/off statin therapy.
Conditions Studied
Interventions
- DRUG Statins
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,456 participants |
| Start Date | 2020-06-10 |
| Est. Completion | 2028-12-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03936361
The ClinicalTrials.gov registry entry for NCT03936361 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 1,456 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,126-participant average among 29 other Intracerebral Hemorrhage trials with a reported enrollment target (29% higher). The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracerebral Hemorrhage appearing as the primary indexed condition, and to 1 intervention - of which Statins is the first listed.
NCT03936361 reports 1 study location spanning 1 distinct geographic area - top geographies include Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03936361 about?
NCT03936361 is a clinical study titled "Statins In Intracerbral Hemorrhage". The SATURN trial aims to determine whether continuation vs. discontinuation of statin drugs after spontaneous lobar intracerebral hemorrhage (ICH) is the best strategy; and whether the decision to continue/discontinue statins should be influenced by an individual's Apolipoprotein-E (APOE) genotype. ...
What is the current status of trial NCT03936361?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 1,456 participants. The study started on 2020-06-10. Estimated completion is 2028-12-31.
What conditions does trial NCT03936361 study?
This clinical trial studies the following conditions: Intracerebral Hemorrhage.
What interventions are being tested in trial NCT03936361?
The interventions under investigation include: Statins (DRUG).
Who is sponsoring clinical trial NCT03936361?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03936361 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Intracerebral Hemorrhage
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial - Part 2
RECRUITING · Phase 3
-
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
RECRUITING · Phase 3
-
Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial
ACTIVE NOT RECRUITING · Phase 3
-
Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III
COMPLETED · Phase 3
-
Hemodynamic ABI Monitor
RECRUITING
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.